AccScience Publishing / TD / Volume 1 / Issue 1 / DOI: 10.36922/td.v1i1.52
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report

Zhe Jiang1 Hongyan Li1* Fei Li1
Show Less
1 Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Tumor Discovery 2022, 1(1), 52
Submitted: 16 March 2022 | Accepted: 29 April 2022 | Published: 6 May 2022
© 2022 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.

Pancreatic cancer
Beijing Municipal Administration of Hospitals’ Youth Program
Top-notch Youth Project of the Supporting Plan for the Construction of High-level Teachers in Beijing-affiliated Universities
Beijing Excellent Talents Training Funding Project
Xuanwu Hospital Huizhi Talent Project

Raimondi S, Maisonneuve P, Lowenfels AB, 2009, Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol, 6(12): 699–708. 


Klein AP, Brune KA, Petersen GM, et al., 2004, Prospective risk of PC in familial PC kindreds. Cancer Res, 64(7): 2634–2638.


Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al., 2009, Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet, 41(9): 986–990.


Wolpin BM, Chan AT, Hartge P, et al., 2009, ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101(6): 424–431. 


Li D, Yeung SC, Hassan MM, et al., 2009, Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137(2): 482–488. 


Blackford A, Parmigiani G, Kensler TW, et al., 2009, Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res, 69(8): 3681–3688.


Moore MJ, Goldstein D, Hamm J, et al., 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol, 25(15): 1960–1966.


Sun J, Wan Z, Chen Y, et al., 2020, Triple drugs co-delivered by a small gemcitabine-based carrier for PC immunochemotherapy. Acta Biomater, 106: 289–300. 


Wu D, Lv J, Zhao R, et al., 2020, PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res, 8: 3–16.


Gautam SK, Kumar S, Dam V, et al., 2020, MUCIN-4 (MUC4) is a novel tumor antigen in PC immunotherapy. Semin Immunol, 14: 101391–101399.


Okusaka T, Furuse J, 2020, Recent advances in chemotherapy for pancreatic cancer: Evidence from Japan and recommendations in guidelines. J Gastroenterol, 55(4): 369–382. 


Schizas D, Charalampakis N, Kole C, et al., 2020, Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev, 86: 102016.


Tivadar ST, McIntosh RS, Chua JX, et al., 2020, Monoclonal antibody targeting sialyl-di-Lewisa-containing internalizing and noninternalizing glycoproteins with cancer immunotherapy development potential. Mol Cancer Ther, 19(3): 790–801.

Conflict of interest
The authors report no conflict of interest.
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing